Zealand Pharma

Contact
zp.dk
+4543281200

Zealand Pharma A/S

Smedeland 36
2600 Glostrup
Denmark
+4543281200
zp.dk
Contact
Profile Products News
Contact

About Zealand Pharma

Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. The products target diseases and symptoms of significant unmet clinical need and commercial potential.

Since 1999, Zealand’s scientists have built a pipeline that includes three compounds in clinical phase II development and two compounds in clinical phase I development. In addition, two compounds are in pre-clinical development.

As part of the Company’s operations, Zealand Pharma has formed clinical development partnerships with leading pharmaceutical companies Sanofi-Aventis and Wyeth.

Read more about Zealand Pharma
Facts about Zealand Pharma
  • Focus : Manufacturer
  • Industry : Biotechnology

Product portfolio of Zealand Pharma

Product portfolio

Show all

Similar companies

Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies
Merck Life Science KGaA

Merck Life Science KGaA

Darmstadt
Manufacturer
Laboratory analysis / Laboratory measurement technology
Biotechnology
Search companies

News about Zealand Pharma

Zealand Pharma

23-Jun-2022 | business & finance

Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design

Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery

Read news
Zealand Pharma

08-Jan-2013 | people

Zealand Pharma appoints new Chief Operating Officer

Zealand Pharma (ZEAL) announces the appointment of Agneta Svedberg as the company’s new Chief Operating Officer.  Effective from 1 February 2013, she will ...

Read news
Zealand Pharma

17-Sep-2012 | research and development

Zealand Pharma advances ZP2929 into Phase I development for the treatment of Type 2 diabetes and/or obesity

First study participant dosed in a Phase I study with novel dual acting glucagon/GLP-1 peptide agonist in partnership with Boehringer Ingelheim

Read news
Zealand Pharma

06-Mar-2012 | research and development

Zealand Pharma and Helsinn announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients

First patients dosed in Phase IIa study of novel GLP-2 peptide agonist

Read news
Zealand Pharma

29-Jun-2011 | research and development

Zealand Pharma presented new preclinical data on ZP2929 in disease models for diabetes and obesity

ZP2929 caused a greater loss in body weight and fat mass as compared to treatment with liraglutide, a marketed GLP-1 agonist

Read news
Zealand Pharma

17-Jun-2011 | research and development

Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity

Boehringer Ingelheim obtains global rights to glucagon/GLP-1 dual agonists, including ZP2929, Zealand Pharma’s lead drug candidate in this class

Read news
Zealand Pharma

01-Jun-2011 | research and development

Zealand Pharma: Additional positive Phase III results with Lyxumia (lixisenatide) for the treatment of Type 2 diabetes

Zealand Pharma A/S announced that its partner, Sanofi has released additional positive results from the global GetGoal Phase III development program with ...

Read news
Zealand Pharma

02-May-2011 | people

Zealand Pharma welcomes Jutta af Rosenborg and Jørgen Lindegaard as new board members

Zealand Pharma announced that Jutta af Rosenborg and Jørgen Lindegaard have been elected as new members to the company’s Board of Directors at the Annual ...

Read news
Show more news about Zealand Pharma

Here you will find Zealand Pharma A/S